Stempeutics Eyes Global Markets For New Crohn's Symptom Cell Therapy
Stempeutics explores stem cell therapy in India for Crohn’s disease-related perianal fistulae while considering entry into other Asian markets.
You may also be interested in...
Daiichi Sankyo also gets right of first negotiation for edaravone, approved in the US and Japan, in other Central and South American markets. Astellas advances its “Rx+” strategy in partnership with iota Biosciences.
The head of global business strategy at ViroMed, one of the gene therapy companies nearing the commercial stage in the US, talks exclusively to Scrip about the South Korean biotech’s strategies, including for pricing and manufacturing, which are emerging as key considerations for developers.
2019 could be a monumental year for the South Korean pharma industry, as several new drug assets await the green light from the US FDA.